EGC Innova Spółka z Ograniczoną Odpowiedzialnością (KRS 0000367283, NIP 7292685616) is a Polish company, headquartered in M. Łódź, Łódzkie voivodeship. EGC INNOVA operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since October 6, 2010. EGC INNOVA's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - EGC Innova
Identity
- Name
- EGC Innova Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- October 6, 2010
- Registry status as of
- November 21, 2025
- Latest entry
- June 30, 2025
- Founding act
- 19.07.2010 R. KANCELARIA NOTARIALNA W ŁODZI NOTARIUSZ BOGNA GAŁĄZKA-MIKINA REPERTORIUM A NR 3476/2010- UMOWA SPÓŁKI
Articles of association history (3)
- July 19, 2010: 19.07.2010 R. KANCELARIA NOTARIALNA W ŁODZI NOTARIUSZ BOGNA GAŁĄZKA-MIKINA REPERTORIUM A NR 3476/2010- UMOWA SPÓŁKI
- June 22, 2011: 22.06.2011R., REPERTORIUM A NR 3464/2011, NOTARIUSZ BOGNA GAŁĄZKA-MIKINA, KANCELARIA NOTARIALNA W ŁODZI, ZMIENIONO § 6 USTĘP 1 UMOWY SPÓŁKI.
- March 19, 2013: 19.03.2013 R., NOTARIUSZ BOGNA GAŁĄZKA-MIKINA, KANCELARIA NOTARIALNA W ŁODZI, REPERTORIUM A NR 1899/2013, ZMIENIONO § 6 UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- ŻELIGOWSKIEGO, 3/5, 90-752, M. ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- M. ŁÓDŹ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - EGC Innova
Credibility rating
51.6 / 100
Average credibility
Insolvency risk
Very low
Low threat
Closure risk
21
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/16 yrs
Board changes
1
1/16 yrs
PKD changes
3
3/16 yrs
Name changes
0
0/16 yrs
Data from 16 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: D (52/100)
Trend: improving (+9.8 pts/year)
Słaba wiarygodność płatnicza – wskaźniki finansowe sugerują podwyższone ryzyko opóźnień lub niewykonania zobowiązań.
Trade credit limit history
Standard limit from 2018–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - EGC Innova
Founded
October 6, 2010
15 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
M. ŁÓDŹ
ŁÓDZKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
6.0 K PLN
120 shares total
Shareholders
4
shareholders
Board
1 person
Filed years
4 years
2018–2024 · profitable: 0/4
Registry entries
26
latest: June 30, 2025
Risk signals
Revenue
0 PLN
2024
Net profit
-273.5 PLN
2024
Assets
10.9 K PLN
2024
Equity
10.9 K PLN
2024
EBITDA
N/A
2024
no depreciation data
Valuation
6.6 K PLN
Low confidence
Low confidence
Public procurement
Trademarks
Reviews
Rate business credibility - EGC Innova.
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
